Geoffrey Shouse, DO

City of Hope National Medical Center

Poster(s):

• 1312 - Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL

• 1404 - A Phase 2 study with Tafasitamab and Zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – TaZa CLL Study

• 1605 - Phase 2 study of the combination of lisocabtagene maraleucel, nivolumab, and ibrutinib in Richter’s transformation - NCT05672173